Pharma Stocks

The board of directors of Biocon are scheduled to meet on December 06, 2025, to consider and approve the proposals for investment in Biocon Biologics, an unlisted material subsidiary of the company.

Emkay Global initiated coverage of Ipca Labs shares with 'Buy' rating and a share price target of ₹1,700 -- a 19 per cent upside from current levels

Complex generics and better mix fuel recovery cycle

The company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic 'Zaynich'

Sudeep Pharma shares opened at ₹733.95, a premium of ₹140.95 or 23.8 per cent

At 10:40 AM, SMS Pharmaceuticals share price was trading 6.77 per cent higher at ₹292.55 per share. In comparison, BSE Sensex was trading 0.73 per cent higher at 85,204.25 levels.

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

On Monday, the rupee advanced amid reports that the RBI resumed efforts to support currency via overseas and onshore markets

Glenmark Pharma shares rose after the company reported a 72.2 per cent surge in profit after tax to ₹610.43 crore in September quarter

Ipca Laboratories share price was trading 6.2 per cent higher at ₹1,382.60 compared to previous session's close of ₹1,302 on the NSE

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Zydus Life Q2 results review: Foreign brokerage Nomura said Zydus Life delivered results above estimates, led by a stronger-than-expected performance in India.

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

Motilal Oswal has initiated coverage on Rubicon Research, a pharmaceutical manufacturing company, with a 'Buy' rating

In the Q2FY26, Cipla reported consolidated revenue from operations of ₹7,589 crore, up 8 per cent year-on-year (Y-o-Y) from ₹7,051 crore in the year-ago period

Dr Reddy's Laboratories has received a Notice of Non-Compliance from Pharmaceutical Drugs Directorate, Canada, regarding its Abbreviated New Drug Submission for Semaglutide Injection.